08:59 AM EDT, 09/16/2025 (MT Newswires) -- Adial Pharmaceuticals ( ADIL ) said Tuesday it received final meeting minutes from its end-of-phase 2 meeting with the US Food and Drug Administration, confirming regulatory alignment on the design of a phase 3 trial for AD04 in alcohol use disorder.

Adial said it is implementing FDA recommendations consistent with meeting outcomes to advance AD04 towards phase 3 development.

Adial Pharmaceuticals ( ADIL ) shares were up 2.6% in recent Tuesday premarket activity.